SUN Pharmaceutical Industries Limited — Fenofibrate Exporter Profile
Indian Pharmaceutical Exporter · #4 for Fenofibrate · $5.7M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #4 Indian exporter of Fenofibrate with $5.7M in export value and 113 verified shipments. SUN Pharmaceutical Industries Limited holds a 7.7% market share in Fenofibrate exports across 10 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Fenofibrate Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Fenofibrate?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BELGIUM | $1.6M | 88 | 72.0% |
| BRAZIL | $154.8K | 4 | 6.9% |
| PHILIPPINES | $117.7K | 7 | 5.2% |
| CANADA | $97.7K | 2 | 4.3% |
| SRI LANKA | $84.3K | 6 | 3.7% |
| MYANMAR | $80.5K | 7 | 3.6% |
| AUSTRALIA | $50.0K | 1 | 2.2% |
| MOROCCO | $40.7K | 1 | 1.8% |
| THAILAND | $4.1K | 1 | 0.2% |
| ROMANIA | $11 | 1 | 0.0% |
SUN Pharmaceutical Industries Limited exports Fenofibrate to 10 countries. The largest destination is BELGIUM accounting for 72.0% of SUN Pharmaceutical Industries Limited's Fenofibrate shipments, followed by BRAZIL (6.9%) and PHILIPPINES (5.2%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fenofibrate from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $1.4M | 74 |
| YUSEN LOGISTICS BENELUX BELGIUM KEETBERGLAAN | BELGIUM | $154.8K | 11 |
| SUN PHARMA CANADA INC | CANADA | $97.7K | 2 |
| M/S. RANBAXY FARMACEUTICA LTDA | BRAZIL | $69.4K | 2 |
| M S IE MEDICA INC | PHILIPPINES | $65.8K | 3 |
| SUN PHARMA ANZ PTY LTD. | AUSTRALIA | $50.0K | 1 |
| M/S. RANBAXY FARMACEUTICA LTDA, | BRAZIL | $50.0K | 1 |
| MYIT MAHAR TRADING CO., LTD. | MYANMAR | $47.4K | 3 |
| SUN PHARMACEUTICALS MOROCCO LLC | MOROCCO | $40.7K | 1 |
| TO THE HONGKONG AND SHANGHAI BANKIN | SRI LANKA | $35.5K | 2 |
SUN Pharmaceutical Industries Limited supplies Fenofibrate to 25 buyers globally. The largest buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by YUSEN LOGISTICS BENELUX BELGIUM KEETBERGLAAN (BELGIUM) and SUN PHARMA CANADA INC (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fenofibrate Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $48.1M worth of Fenofibrate through 2,794 shipments from 168 suppliers to 81 countries, serving 368 buyers globally. SUN Pharmaceutical Industries Limited contributes $5.7M to this total, accounting for 7.7% of India's Fenofibrate exports. SUN Pharmaceutical Industries Limited ships Fenofibrate to 10 countries through 25 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Fenofibrate Exports?
SUN Pharmaceutical Industries Limited's average Fenofibrate shipment value is $50.0K per consignment, based on 113 shipments totaling $5.7M. The largest destination is BELGIUM (72.0% of SUN Pharmaceutical Industries Limited's Fenofibrate exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Fenofibrate Exporters?
SUN Pharmaceutical Industries Limited ranks #4 among 168 Indian Fenofibrate exporters with a 7.7% market share. The top 3 exporters are HETERO LABS LIMITED ($8.3M), CIPLA LIMITED ($7.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($5.7M). SUN Pharmaceutical Industries Limited processed 113 shipments to 10 destination countries.
What Fenofibrate Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| FENOFIBRATE CAPSULES 200MG PACK :4x7s Ba | $224.2K | 6 |
| FENOFIBRATE CAPSULES 267MG PACK : 4x7s B | $124.6K | 5 |
| FENOFIBRATE CAPSULES 200MG PACK : 4x7s B | $98.3K | 6 |
| HSN CODE:30049099 SAP CODE:1113750 TAROFENOFIBRATE E TABS 145MG E.TAB.CONT:FENOFIBRATE PH.EUR.145MG PACK : 100S BOTTL | $50.0K | 1 |
| FENOFIBRAT TERAPIA TAB 145MG PACK : BOX3X10S BATCH : MHF0350A MHF0369A EACH TABCONTS: FENOFIBRATE PH.EUR. 145MG | $50.0K | 1 |
| FENOFIBRATE RBX TAB.145MG,E.FILM COAT TAB.CON:FENOFIB.PH.EUR.145MG,PACK:Box3x10s,Batch:MHG0101A MFD: 16.01.25 EXP:31.12. | $50.0K | 1 |
| FENOFIBRATO PENSA TAB 160MG PACK : Box3x10s Batch : DFF7028B, DFF8272A EACH TABLETS CONTAINS: FENOFIBRATE PH.EUR. 160MG | $50.0K | 1 |
| FENOFIBRATE TAB 160MG 3X10b BR PACK:BOX3X10s BATCH:DFG1098A,DFG1099A EACH CONTS.FENOFIBRATE TAB 160MG | $50.0K | 1 |
| HSN CODE:30049099 SAP CODE:1113750 TAROFENOFIBRATE E TABS 145 MG EACH TABLET CONTAINS:FENOFIBRATE PH.EUR. 145 MG PACK : | $47.7K | 1 |
| STANLIP TAB 160 mg (FENOFIBRATE BP EQUIV | $47.4K | 3 |
SUN Pharmaceutical Industries Limited exports 99 distinct Fenofibrate formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FENOFIBRATE CAPSULES 200MG PACK :4x7s Ba with 6 shipments worth $224.2K.
Regulatory Requirements: Exporting Fenofibrate to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Fenofibrate to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Fenofibrate Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | HETERO LABS LIMITED | $8.3M | 338 | 8 | $24.4K |
| 3 | CIPLA LIMITED | $7.1M | 329 | 3 | $21.7K |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $5.7M | 113 | 10 | $50.0K |
| 6 | AJANTA PHARMA LIMITED | $4.7M | 105 | 3 | $44.7K |
| 7 | MANKIND PHARMA LIMITED | $4.2M | 283 | 1 | $14.8K |
SUN Pharmaceutical Industries Limited ranks #4 among 168 Indian Fenofibrate exporters. Average shipment value of $50.0K compared to the market average of $286.5K. The closest competitors by value are HETERO LABS LIMITED and CIPLA LIMITED.
Which Indian Ports Ship Fenofibrate Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 361 | 12.9% |
| SAHAR AIR | 281 | 10.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 229 | 8.2% |
| DELHI AIR CARGO ACC (INDEL4) | 227 | 8.1% |
| JNPT/ NHAVA SHEVA SEA | 203 | 7.3% |
| DELHI AIR | 143 | 5.1% |
| HYDERABAD ICD | 125 | 4.5% |
| JNPT | 115 | 4.1% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Fenofibrate Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Fenofibrate, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fenofibrate — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fenofibrate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 118 individual customs records matching SUN Pharmaceutical Industries Limited exporting Fenofibrate, covering 99 formulations to 10 countries via 25 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 81+ countries, 368+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fenofibrate Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Fenofibrate exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Fenofibrate Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fenofibrate. For current shipment-level data, contact TransData Nexus.